Patents Examined by Craig D Ricci
  • Patent number: 11667627
    Abstract: A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: June 6, 2023
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Peter Brent Sampson, Miklos Feher, Heinz W. Pauls
  • Patent number: 11666555
    Abstract: Pharmaceutical compositions comprising a RelA enzyme inhibitor and a bactericidal antibiotic, wherein said RelA enzyme inhibitor binds to the RelA enzyme in bacteria to reduce biofilm formation and to degrade biofilms that have been formed. The pharmaceutical compositions can be used to treat bacterial biofilm diseases.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 6, 2023
    Assignee: DREXEL UNIVERSITY
    Inventors: Hai-Feng Ji, Garth David Ehrlich, Donald Carl Hall, Jr., Jaroslaw E. Krol, John P. Cahill
  • Patent number: 11667649
    Abstract: Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. Also disclosed are methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 11, 2021
    Date of Patent: June 6, 2023
    Assignee: Nuvalent, Inc.
    Inventors: Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul
  • Patent number: 11654091
    Abstract: A lotion for the topical application to reduce a swimmer's friction when swimming in water made by combining an aqueous phase comprising and at least one humectant with an oil phase. The at least one humectant is present in the aqueous phase in the range of from 45 to 97 wt. %. The oil phase comprises at least one surfactant and at least one oil, and is present in the lotion in the range of about 5 to 45 wt. %. The surfactant is present in the oil phase in the range of from about 0.1 to 25 wt. %. The lotion is stable, homogenous and hydrophobic, and reduces friction when swimming in water, with the lotion applied to a swimmer.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: May 23, 2023
    Assignee: Shear Kershman Laboratories, Inc
    Inventors: Alvin Kershman, Jeff Shear
  • Patent number: 11649247
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: May 16, 2023
    Assignee: Eli Lilly and Company
    Inventors: Renato Alejandro Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Patric James Hahn, Zoran Rankovic
  • Patent number: 11643394
    Abstract: The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: May 9, 2023
    Assignees: Icahn School of Medicine at Mount Sinai, The United States Government as represented by the Department of Veterans Affairs, The Research Foundation for the State University of New York
    Inventors: Sandeep Mallipattu, Bhaskar Das
  • Patent number: 11643420
    Abstract: The present invention provides compounds and pharmaceutical compositions including the compounds for the treatment of a skin disease associated with proteolytic activity of one or more KLK proteases, wherein the compounds are according to formula (I): wherein R is as described herein.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: May 9, 2023
    Assignee: MOLECULAR SKIN THERAPEUTICS, INC.
    Inventors: Andreas Betz, Robert Zamboni
  • Patent number: 11634396
    Abstract: Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: April 25, 2023
    Assignee: EPIODYNE, INC.
    Inventors: Julio Cesar Medina, Alok Nerurkar, Corinne Sadlowski, Frederick Seidl, Heng Cheng, Jason Duquette, John Lee, Martin Holan, Pingyu Ding, Xiaodong Wang, Tien Widjaja, Thomas Nguyen, Ulhas Bhatt, Yihong Li, Zhi-liang Wei
  • Patent number: 11629156
    Abstract: A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: April 18, 2023
    Assignee: Eli Lilly and Company
    Inventors: Renato Alejandro Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Raymond Gilmour, Patric James Hahn, Zoran Rankovic
  • Patent number: 11629154
    Abstract: The present invention provides a compound which has an effect of inhibiting amyloid ßproduction, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid ßproteins. A compound of Formula (I) wherein R3 is each independently alkyl optionally substituted with halogen, cyano, alkyloxy, haloalkyloxy or non-aromatic carbocyclyl, or the like; t is integer from 0 to 3; R5 is a hydrogen atom or halogen; R6 is selected from the group consisting of a hydrogen atom, halogen, and substituted or unsubstituted alkyl; ring B is a substituted or unsubstituted pyrazine or the like; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: April 18, 2023
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Genta Tadano, Shinji Suzuki, Ken-ichi Kusakabe
  • Patent number: 11612635
    Abstract: There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux esophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinson's disease, MS, Alzheimer's Disease, Motor Neuron Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: March 28, 2023
    Inventor: Thomas Julius Borody
  • Patent number: 11596614
    Abstract: Treatment of intrahepatic cholestatic diseases by therapy with seladelpar or a salt thereof.
    Type: Grant
    Filed: April 3, 2021
    Date of Patent: March 7, 2023
    Assignee: CymaBay Therapeutics, Inc.
    Inventors: Pol Boudes, Charles A. McWherter
  • Patent number: 11598778
    Abstract: The present invention relates to biomarkers associated with CTCL, including TOX, PLS3, KIR3DL2, GATA3 and RUNX3, where increased expression, relative to normal control, of one or more of TOX, PLS3, KIR3DL2, and/or GATA3 is associated with CTCL and decreased expression of RUNX3, relative to normal control, is associated with CTCL. One or more of these biomarkers may be used to diagnose CTCL and/or design and monitor treatment.
    Type: Grant
    Filed: June 18, 2021
    Date of Patent: March 7, 2023
    Assignee: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Larisa J. Geskin, Brittany Lynn O'Neill Dulmage, Louis D. Falo, Jr.
  • Patent number: 11596651
    Abstract: Disclosed herein are compound embodiments that are useful for treating a variety of diseases, particularly neurological diseases, motor neuron diseases, copper deficiency-related diseases, and/or mitochondrial deficiencies. The compound embodiments described herein also can be used in PET methods. Also disclosed herein are embodiments of methods of making and using the compound embodiments, as well as pharmaceutical formulations comprising the disclosed compound embodiments.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: March 7, 2023
    Assignee: Oregon State University
    Inventors: Joseph Beckman, James Hurst, John Sirois, Chris Beaudry
  • Patent number: 11596617
    Abstract: Biologically active cannabidiol analogs comprising a compound of the formula wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: March 7, 2023
    Assignee: UNIVERSITY OF MISSISSIPPI
    Inventors: Mahmoud A. ElSohly, Soumyajit Majumdar, Waseem Gul, Mohammad Khalid Ashfaq, Kenneth Joseph Sufka, Hannah Marie Harris
  • Patent number: 11591363
    Abstract: The present invention relates to a cocrystal of beta-sitosterol or a pharmaceutically acceptable ester thereof or an edible acceptable ester thereof and an organic carboxylic acid coformer, an hydrate crystal form of beta-sitosterol having 1.25 molecules of water per molecule of beta-sitosterol and a combination that comprises a cocrystal of beta-sitosterol and an organic carboxylic acid; and the hydrate crystal form of beta-sitosterol having 1.25 molecules of water per molecule of beta-sitosterol. It also relates to processes for their preparation, and compositions containing them, as well as their use as a medicament or dietary supplement or functional food, and in particular in the prophylaxis and/or treatment of a disease or conditions that involves an alteration of lipid metabolism, circulating levels of lipids in the blood and/or lipid composition in tissues and organs.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 28, 2023
    Assignees: CENTER FOR INTELLIGENT RESEARCH IN CRYSTAL ENGINEERING, S.L., ALIMENTOMICA, S.L.
    Inventors: Rafel Prohens López, Rafael Barbas Cañero, Anna Portell Bueso, Mariona Palou March, Francisca Serra Vich, Andreu Palou March
  • Patent number: 11584716
    Abstract: A process A for the production of compounds of formula I is provided. Process A includes Step A of reacting compounds of formula II with 2,3-dihalopropionitrile or 2-haloacrylonitrile in the presence of DIPEA. A process B for the production of compounds of formula III is also provided. Process B includes Step B of reacting compounds of formula I with Br2 in the presence of DIPEA. A process C for the production of compounds of formula IV is further provided. Process C includes Step C of reacting compounds of formula III with di(C1-C4-alkoxy)methane and either POCl3, or a mixture comprising POCl3 and DMF, in the presence of DIPEA. Additionally, the use of DIPEA as a base in the production of compounds of formula I, compounds of formula III, or compounds of formula IV is provided.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: February 21, 2023
    Assignee: BASF AGRO B.V.
    Inventors: David A. Cortes, Ryan Michael Phillips
  • Patent number: 11572374
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: February 7, 2023
    Assignee: AMGEN INC.
    Inventors: John R. Butler, Daniel Erlanson, Russell Graceffa, Jeffrey Iwig, Joon Won Jeong, Ryan D. White, Yongwei Wu, Shuyan Yi, Xiao Mei Zheng, Jesse M. McFarland, Abhisek Banerjee
  • Patent number: 11570990
    Abstract: A method of controlling phytopathogenic diseases on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a combination of components (A) and (B) in a synergistically effective amount, wherein component (A) is a compound of formula I compound of formula I wherein R is hydrogen or methoxy; Q is R1 is hydrogen, halogen or C1-C6alkyl; R2 is hydrogen, halogen, C1-C6alkyl, C2-C6alkenyl, C3-C6alkinyl, C3-C6cycloalkyl-C3-C6alkinyl, halophenoxy, halophenyl-C3-C6alkinyl, C(C1-C4alkyl)=NO—C1-C4alkyl, C1-C6haloalkyl, C1-C6haloalkoxy, C2-C6haloalkenyl, or C2-C6haloalkenyloxy; R3 is hydrogen, halogen, C1-C6alkyl; R4, R5 and R6, independently from each other, are hydrogen, halogen or —?—R7; with the proviso that at least one of R4, R5 and R6 is different from hydrogen; R7 is hydrogen, C1-C6alkyl, C1-C6haloalkyl or C1-C4alkoxyalkyl; and R8 is hydrogen or methoxy; and agrochemically acceptable salts/isomers/structural is
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: February 7, 2023
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Harald Walter, Daniel Stierli
  • Patent number: 11572372
    Abstract: Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I).
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: February 7, 2023
    Assignee: Medshine Discovery Inc.
    Inventors: Lifang Wu, Fei Sun, Jinhua Du, Charles Z. Ding, Shuhui Chen, Xiquan Zhang, Hongjiang Xu, Ling Yang